7 Validation of the anti-obesity medication TRAP protocol
It was also observed a reduction in body weight and BMI similar to that described in the general population.5,15 This effect has been explained by the delay in gastric emptying and satiety caused by this group of anti-diabetics.4,5 The prevalence of obesity in the KT recipient population is high
Furthermore, BPC-157 has been shown to support the healing of both soft tissues (like ligaments and tendons) and hard tissues (like bone), making it an effective tool for a comprehensive recovery process following bone injuries
If you are starting a program with us or another provider, it is vital to disclose all supplements you are taking so your dosage can be managed safely
These variants do not predict who will tolerate retatrutide, who will experience side effects, or who will respond to any specific medication, but they can be part of the broader metabolic context informing a provider conversation
Most patients report no noticeable change in appetite suppression, side effects, or energy levels, particularly when switching between equivalent doses